![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
67
PharmaCompass offers a list of Tofacitinib Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tofacitinib Citrate manufacturer or Tofacitinib Citrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tofacitinib Citrate manufacturer or Tofacitinib Citrate supplier.
PharmaCompass also assists you with knowing the Tofacitinib Citrate API Price utilized in the formulation of products. Tofacitinib Citrate API Price is not always fixed or binding as the Tofacitinib Citrate Price is obtained through a variety of data sources. The Tofacitinib Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tasocitinib Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tasocitinib Citrate, including repackagers and relabelers. The FDA regulates Tasocitinib Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tasocitinib Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tasocitinib Citrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tasocitinib Citrate supplier is an individual or a company that provides Tasocitinib Citrate active pharmaceutical ingredient (API) or Tasocitinib Citrate finished formulations upon request. The Tasocitinib Citrate suppliers may include Tasocitinib Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Tasocitinib Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tasocitinib Citrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Tasocitinib Citrate active pharmaceutical ingredient (API) in detail. Different forms of Tasocitinib Citrate DMFs exist exist since differing nations have different regulations, such as Tasocitinib Citrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tasocitinib Citrate DMF submitted to regulatory agencies in the US is known as a USDMF. Tasocitinib Citrate USDMF includes data on Tasocitinib Citrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tasocitinib Citrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tasocitinib Citrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tasocitinib Citrate Drug Master File in Japan (Tasocitinib Citrate JDMF) empowers Tasocitinib Citrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tasocitinib Citrate JDMF during the approval evaluation for pharmaceutical products. At the time of Tasocitinib Citrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tasocitinib Citrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tasocitinib Citrate Drug Master File in Korea (Tasocitinib Citrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tasocitinib Citrate. The MFDS reviews the Tasocitinib Citrate KDMF as part of the drug registration process and uses the information provided in the Tasocitinib Citrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tasocitinib Citrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tasocitinib Citrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tasocitinib Citrate suppliers with KDMF on PharmaCompass.
A Tasocitinib Citrate written confirmation (Tasocitinib Citrate WC) is an official document issued by a regulatory agency to a Tasocitinib Citrate manufacturer, verifying that the manufacturing facility of a Tasocitinib Citrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tasocitinib Citrate APIs or Tasocitinib Citrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Tasocitinib Citrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Tasocitinib Citrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tasocitinib Citrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tasocitinib Citrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tasocitinib Citrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tasocitinib Citrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tasocitinib Citrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tasocitinib Citrate suppliers with NDC on PharmaCompass.
Tasocitinib Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tasocitinib Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tasocitinib Citrate GMP manufacturer or Tasocitinib Citrate GMP API supplier for your needs.
A Tasocitinib Citrate CoA (Certificate of Analysis) is a formal document that attests to Tasocitinib Citrate's compliance with Tasocitinib Citrate specifications and serves as a tool for batch-level quality control.
Tasocitinib Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Tasocitinib Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tasocitinib Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Tasocitinib Citrate EP), Tasocitinib Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tasocitinib Citrate USP).